Alfonso Iorio
#167,481
Most Influential Person Now
Researcher
Alfonso Iorio's AcademicInfluence.com Rankings
Alfonso Iorioengineering Degrees
Engineering
#7470
World Rank
#8846
Historical Rank
Biomedical Engineering
#760
World Rank
#772
Historical Rank
Electrical Engineering
#2338
World Rank
#2446
Historical Rank
Applied Physics
#2599
World Rank
#2640
Historical Rank

Download Badge
Engineering
Why Is Alfonso Iorio Influential?
(Suggest an Edit or Addition)Alfonso Iorio's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Interventions for enhancing medication adherence. (2008) (2134)
- Discrimination and Calibration of Clinical Prediction Models: Users’ Guides to the Medical Literature (2017) (713)
- Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. (2001) (553)
- D-dimer testing to determine the duration of anticoagulation therapy. (2006) (527)
- Aryl hydrocarbon receptor control of a disease tolerance defence pathway (2014) (502)
- Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. (1998) (483)
- Guideline for opioid therapy and chronic noncancer pain (2017) (449)
- Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients (2015) (437)
- Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH) (2012) (379)
- Impact of Thrombophilia on Risk of Arterial Ischemic Stroke or Cerebral Sinovenous Thrombosis in Neonates and Children: A Systematic Review and Meta-Analysis of Observational Studies (2010) (363)
- The GRADE Working Group clarifies the construct of certainty of evidence. (2017) (335)
- Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. (2010) (319)
- Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study (2011) (273)
- Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review (2010) (272)
- Effectiveness of computerized decision support systems linked to electronic health records: a systematic review and meta-analysis. (2014) (256)
- Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis (2011) (246)
- Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. (2000) (229)
- Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient‐level meta‐analysis (2010) (200)
- Patient-Level Meta-analysis: Effect of Measurement Timing, Threshold, and Patient Age on Ability of d-Dimer Testing to Assess Recurrence Risk After Unprovoked Venous Thromboembolism (2010) (170)
- Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males (2019) (151)
- Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta‐analysis of randomized controlled trials (2015) (148)
- Low‐molecular‐weight heparin for the long‐term treatment of symptomatic venous thromboembolism: meta‐analysis of the randomized comparisons with oral anticoagulants (2003) (148)
- Association of Anticholinergic Burden with Cognitive and Functional Status in a Cohort of Hospitalized Elderly: Comparison of the Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale (2013) (147)
- Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal A systematic review and meta-analysis (2016) (127)
- Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. (2011) (119)
- ISTH guidelines for treatment of thrombotic thrombocytopenic purpura (2020) (118)
- Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. (2005) (118)
- Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. (2009) (117)
- Individual participant data meta-analyses compared with meta-analyses based on aggregate data. (2011) (117)
- Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. (2006) (112)
- COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine (2020) (112)
- Use of GRADE for assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. (2020) (109)
- Inhibitor development in haemophilia according to concentrate (2015) (107)
- GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. (2017) (106)
- Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study (2016) (104)
- Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting (2010) (102)
- Psychosocial aspects of haemophilia: a systematic review of methodologies and findings (2012) (102)
- Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopatic deep venous thrombosis. (2001) (95)
- Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. (2011) (95)
- Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. (2011) (94)
- Recommendations for the Management of Intracranial Haemorrhage – Part I: Spontaneous Intracerebral Haemorrhage (2006) (87)
- Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis (2013) (87)
- Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographics (2014) (86)
- Bone mineral density in haemophilia patients (2010) (83)
- Development of a Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Study Protocol (2016) (82)
- ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura (2020) (82)
- Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis (2008) (81)
- Risk factors for hospital readmission of elderly patients. (2013) (79)
- McMaster RARE‐Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome (2018) (78)
- Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment (2009) (78)
- Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data (2015) (72)
- Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project (2018) (68)
- Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH (2017) (64)
- Inhibitor development in previously treated hemophilia A patients: a systematic review, meta‐analysis, and meta‐regression (2013) (62)
- Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis (2016) (62)
- Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: The extended DACUS study (2011) (61)
- Drug–drug interactions in a cohort of hospitalized elderly patients (2013) (61)
- Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000–18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database (2020) (60)
- Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta‐analysis (2017) (58)
- Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors (2012) (57)
- Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement (2017) (54)
- Prognostic factors for VTE and Bleeding in Hospitalized Medical Patients: a systematic review and meta-analysis. (2020) (54)
- Thrombosis in Inherited Fibrinogen Disorders (2017) (52)
- Uncertainties in baseline risk estimates and confidence in treatment effects (2012) (51)
- Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. (2010) (50)
- Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behçet's disease and deep vein thrombosis. (2004) (50)
- Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A (2015) (50)
- Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. (2011) (49)
- Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. (2010) (49)
- Haemophilia Experiences, Results and Opportunities (HERO) Study: Influence of haemophilia on interpersonal relationships as reported by adults with haemophilia and parents of children with haemophilia (2014) (49)
- Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. (2011) (48)
- Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. (2015) (48)
- The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A (2016) (48)
- NHF‐McMaster Guideline on Care Models for Haemophilia Management (2016) (48)
- Clotting factor concentrate switching and inhibitor development in hemophilia A. (2012) (47)
- Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa (2014) (45)
- IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. (2015) (45)
- The GRADE evidence-to-decision framework: a report of its testing and application in 15 international guideline panels (2015) (45)
- Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. (1995) (44)
- Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting (2007) (43)
- Systematic reviews experience major limitations in reporting absolute effects. (2016) (43)
- The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta‐analysis (2020) (43)
- In-hospital death and adverse clinical events in elderly patients according to disease clustering: the REPOSI study. (2010) (42)
- Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations (2018) (41)
- A Deep Learning Method to Automatically Identify Reports of Scientifically Rigorous Clinical Research from the Biomedical Literature: Comparative Analytic Study (2018) (40)
- Pharmacokinetics and the transition to extended half‐life factor concentrates: communication from the SSC of the ISTH (2018) (40)
- The World Federation of Hemophilia Annual Global Survey 1999‐2018 (2020) (40)
- Emicizumab and thrombosis: The story so far (2019) (40)
- Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey. (2014) (39)
- A systematic review found that deviations from intention-to-treat are common in randomized trials and systematic reviews. (2017) (38)
- Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo) (2016) (38)
- In‐hospital death according to dementia diagnosis in acutely ill elderly patients: the REPOSI study (2011) (37)
- Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates (2017) (37)
- Using pharmacokinetics to individualize hemophilia therapy. (2017) (36)
- The good use of plasma. A critical analysis of five international guidelines. (2008) (35)
- Intracranial Haemorrhage in Patients on Antithrombotics: Clinical Presentation and Determinants of Outcome in a Prospective Multicentric Study in Italian Emergency Departments (2006) (34)
- The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters (2013) (33)
- Adverse clinical events and mortality during hospitalization and 3 months after discharge in cognitively impaired elderly patients. (2013) (33)
- Comparative pharmacokinetics of two extended half‐life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference? (2019) (33)
- Defining certainty of net benefit: a GRADE concept paper (2019) (32)
- Hemophilia trials in the twenty‐first century: Defining patient important outcomes (2019) (32)
- Switching to extended half‐life products in Canada – preliminary data (2017) (31)
- Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes (2018) (31)
- The McMaster Optimal Aging Portal: Usability Evaluation of a Unique Evidence-Based Health Information Website (2016) (31)
- Authors seldom report the most patient-important outcomes and absolute effect measures in systematic review abstracts. (2017) (31)
- Central nervous system bleeding in patients with rare bleeding disorders (2012) (30)
- Strategies for eliciting and synthesizing evidence for guidelines in rare diseases (2019) (29)
- Haemophilia Experiences, Results and Opportunities (HERO) study: treatment‐related characteristics of the population (2015) (29)
- Withdrawal of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation. (1999) (28)
- A critical appraisal of chronic kidney disease mineral and bone disorders clinical practice guidelines using the AGREE II instrument (2017) (28)
- Concentrate‐related inhibitor risk: is a difference always real? (2011) (28)
- Low-Molecular-Weight Heparin and Cancer Survival: Review of the Literature and Pooled Analysis of 1,726 Patients Treated for at Least Three Months (2003) (27)
- Increased Plasma Levels of Tissue Factor Pathway Inhibitor (TFPI) after n-3 Polyunsaturated Fatty Acids Supplementation in Patients with Chronic Atherosclerotic Disease (1996) (27)
- Individual participant data meta-analyses compared with meta-analyses based on aggregate data (2011) (26)
- Reporting, handling and assessing the risk of bias associated with missing participant data in systematic reviews: a methodological survey (2015) (26)
- Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA (2017) (26)
- Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. (2010) (26)
- Applicability of the AGREE II instrument in evaluating the development process and quality of current National Academy of Clinical Biochemistry guidelines. (2012) (26)
- Systematic reviews do not adequately report or address missing outcome data in their analyses: a methodological survey. (2018) (25)
- Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. (2020) (23)
- Miconazole Oral Gel Potentiates Warfarin Anticoagulant Activity (2000) (23)
- Cardiovascular disease (CVD) in Canadians with haemophilia: Age‐Related CVD in Haemophilia Epidemiological Research (ARCHER study) (2015) (23)
- Care models in the management of haemophilia: a systematic review (2016) (23)
- Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions (2015) (23)
- Obtaining and managing data sets for individual participant data meta-analysis: scoping review and practical guide (2019) (23)
- A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. (2019) (22)
- World Federation of Hemophilia Gene Therapy Registry (2020) (22)
- Intracranial bleeding: epidemiology and relationships with antithrombotic treatment in 241 cerebral hemorrhages in Reggio Emilia. (2002) (22)
- Developing methodology for the creation of clinical practice guidelines for rare diseases: A report from RARE-Bestpractices (2015) (22)
- Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization (2019) (21)
- Researching what matters to improve chronic pain care in Canada: A priority-setting partnership process to support patient-oriented research (2018) (21)
- Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity (2014) (21)
- Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS‐Hemo project (2020) (21)
- Prophylaxis of venous thromboembolism in elderly patients with multimorbidity (2013) (21)
- Individualizing Factor Replacement Therapy in Severe Hemophilia (2015) (21)
- Pharmacokinetics of plasma‐derived vs. recombinant FVIII concentrates: a comparative study (2015) (21)
- Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A (2019) (21)
- Performance of recalibrated ReFacto® laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one‐stage assays after infusion of recalibrated ReFacto® (B‐domain deleted recombinant factor VIII) (2009) (21)
- A systematic review of definitions and reporting of bleeding outcome measures in haemophilia (2015) (20)
- Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction. (1995) (20)
- Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol (2016) (20)
- Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis (2017) (19)
- Integrated multidisciplinary care for the management of chronic conditions in adults: an overview of reviews and an example of using indirect evidence to inform clinical practice recommendations in the field of rare diseases (2016) (19)
- Selective outcome reporting: telling and detecting true lies. The state of the science (2010) (19)
- Small intestinal bacterial overgrowth and warfarin dose requirement variability. (2010) (19)
- Increasing the quantity and quality of searching for current best evidence to answer clinical questions: protocol and intervention design of the MacPLUS FS Factorial Randomized Controlled Trials (2014) (18)
- Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy. (2011) (18)
- Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH (2020) (18)
- Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura (2020) (18)
- The demographics, treatment characteristics and quality of life of adult people with haemophilia in China – results from the HERO study (2017) (18)
- Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews. (2020) (17)
- Accuracy and Acceptability of Wrist-Wearable Activity-Tracking Devices: Systematic Review of the Literature (2021) (17)
- Research and policy implications of a recently published controlled study in previously untreated haemophilia patients at high risk of inhibitor development (2017) (17)
- Patient data meta‐analysis of Post‐Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF‐PFM (2014) (17)
- Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. (2017) (17)
- Impact of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A Patients: A Historically Controlled Observational Study (2019) (17)
- Impact of missing participant data for dichotomous outcomes on pooled effect estimates in systematic reviews: a protocol for a methodological study (2014) (17)
- Cardiovascular disease prevalence and relevance in haemophilia: a scoping review (2015) (17)
- Inhibitor development in non-severe haemophilia across Europe (2015) (17)
- Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). (2009) (17)
- A methodological survey of the analysis, reporting and interpretation of Absolute Risk ReductiOn in systematic revieWs (ARROW): a study protocol (2013) (16)
- Audit of the clinical use of fresh-frozen plasma in Umbria: study design and results of the pilot phase. (2008) (16)
- Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B. (2014) (16)
- Factor VIII products and inhibitors in severe hemophilia A. (2013) (16)
- Successful treatment with rFVIIa of spontaneous intracerebral hemorrhage in a patient with mechanical prosthetic heart valves. (2005) (15)
- Comparison of Disease Clusters in Two Elderly Populations Hospitalized in 2008 and 2010 (2013) (15)
- Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup (2019) (15)
- Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism. (2017) (15)
- World bleeding disorders registry: The pilot study (2018) (15)
- Prevalence and characteristics of antidepressant drug prescriptions in older Italian patients (2011) (15)
- Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the HERO qualitative study (2015) (15)
- Non‐severe haemophilia: Is it benign? – Insights from the PROBE study (2020) (15)
- Peginterferon Plus Ribavirin for Chronic Hepatitis C in Patients With Human Immunodeficiency Virus (2009) (15)
- Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt‐PA for pulmonary embolism (1997) (15)
- FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies (2016) (14)
- High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance (2013) (14)
- Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire (2017) (14)
- Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A (2020) (14)
- Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation. (2013) (14)
- Point of care ultrasound in haemophilia: Building a strong foundation for clinical implementation (2017) (14)
- Patient-level compared with study-level meta-analyses demonstrate consistency of D-dimer as predictor of venous thromboembolic recurrences. (2013) (14)
- Comorbidities in persons with haemophilia aged 60 years or more compared with age‐matched people from the general population (2018) (14)
- Methodology for the development of the NHF‐McMaster Guideline on Care Models for Haemophilia Management (2016) (13)
- Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, double-blind crossover study. (2010) (13)
- Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. (2010) (13)
- McMaster Optimal Aging Portal: an evidence-based database for geriatrics-focused health professionals (2017) (13)
- Developing a two‐sided intervention to facilitate shared decision‐making in haemophilia: decision boxes for clinicians and patient decision aids for patients (2014) (13)
- Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data (2017) (13)
- Clinical trials and haemophilia: does the Bayesian approach make the ideal and desirable good friends? (2009) (13)
- Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours (2015) (13)
- Point of care ultrasonography in haemophilia care: recommendations for training and competency evaluation (2015) (13)
- Test‐retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains (2018) (13)
- Calculation of absolute risk for important outcomes in patients with and without a prognostic factor of interest. (2019) (13)
- Mesenteric-portal Vein Thrombosis in a Patient with Hyperhomocysteinemia and Heterozygous for 20210A Prothrombin Allele (2000) (12)
- Patient‐relevant health outcomes for hemophilia care: Development of an international standard outcomes set (2021) (12)
- What is the role for population pharmacokinetics in hemophilia (2017) (12)
- Development of haemophilic arthropathy of the ankle: results of a Delphi consensus survey on potential contributory factors (2015) (12)
- Management of Patients With Unprovoked Venous Thromboembolism: An Evidence-Based and Practical Approach (2013) (12)
- Focusing in on use of pharmacokinetic profiles in routine hemophilia care (2018) (12)
- Psychological interventions for people with hemophilia. (2012) (12)
- Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes (2020) (11)
- Switching patients in the age of long-acting recombinant products? (2019) (11)
- Recommended Primary Outcomes for Clinical Trials Evaluating Hemostatic Blood Products and Agents in Patients with Bleeding: Proceedings of a National Heart Lung and Blood Institute and United States Department of Defense Consensus Conference. (2021) (11)
- Large scale studies assessing anti‐factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more (2017) (11)
- Pharmacokinetic Optimisation of the Treatment of Deep Vein Thrombosis (1997) (11)
- Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach (2019) (11)
- Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review (2019) (11)
- The association between platelet transfusions and mortality in patients with critical illness (2019) (11)
- Healthcare provider knowledge, attitudes, beliefs, and practices surrounding the prescription of opioids for chronic non-cancer pain in North America: protocol for a mixed-method systematic review (2018) (11)
- Patterns of tertiary prophylaxis in Canadian adults with severe and moderately severe haemophilia B (2014) (11)
- Minimal dataset for post‐registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH (2017) (10)
- Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type1 diabetic patients (2007) (10)
- GRADE Guidelines 34: Updated GRADE guidance for imprecision rating using a minimally contextualized approach. (2022) (10)
- Exploring regional variations in the cross‐cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study (2019) (10)
- User Experiences of the McMaster Optimal Aging Portal’s Evidence Summaries and Blog Posts: Usability Study (2016) (10)
- Emicizumab state‐of‐the‐art update (2022) (10)
- Dermatan sulphate in heparin-induced thrombocytopenia (1994) (10)
- Joint Bleeding Tendencies in Adult Patients With Hemophilia: It’s Not All Pharmacokinetics (2019) (10)
- An individual participant data meta-analysis of 13 randomized trials to evaluate the impact of prophylactic use of heparin in oncological patients (2017) (10)
- Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. (2020) (9)
- Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients (2019) (9)
- If You Build It, Who Will Come? A Description of User Characteristics and Experiences With the McMaster Optimal Aging Portal (2017) (9)
- Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series (2017) (9)
- Prescriber adherence to guidelines for chronic noncancer pain management with opioids: Systematic review and meta-analysis. (2020) (9)
- Prevention of venous thromboembolism after major orthopedic surgery: summing up evidence about old and new antithrombotic agents (2004) (9)
- Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment. (2020) (9)
- Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A. (2015) (9)
- Fibrinogen Degradation Products Generation is the Major Determinant of Platelet Inhibition Induced by Plasminogen Activators in Platelet-rich Plasma (1993) (9)
- Understanding stakeholder important outcomes and perceptions of equity, acceptability and feasibility of a care model for haemophilia management in the US: a qualitative study (2016) (9)
- A systematic review of using and reporting survival analyses in acute lymphoblastic leukemia literature (2016) (9)
- A taxonomy and framework for identifying and developing actionable statements in guidelines suggests avoiding informal recommendations. (2021) (9)
- The haemophilia certification system in Canada. (2014) (9)
- Prehospital fresh frozen plasma: Universal life saver or treatment in search of a target population? (2018) (9)
- Performance comparison of three assay methods used in fasting and postmethionine load plasma homocysteine determinations from patients with vascular disease. (2005) (9)
- Different mechanisms regulate phosphatidylserine synthesis in rat cerebral cortex (1997) (8)
- Impact of Persistent Antiphospholipid Antibodies on Symptomatic Thromboembolism In Children: A Systematic Review & Meta-Analysis [Observational Studies] (2010) (8)
- Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study (2013) (8)
- Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database (2021) (8)
- Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption (2017) (8)
- Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the HERO qualitative study (2015) (8)
- Epidemiology of Inhibitors in Hemophilia (2014) (8)
- The Khorana Score for the prediction of venous thromboembolism in patients with solid cancer: An individual patient data meta-analysis (2017) (7)
- Joint WFH‐ISTH session: issues in clinical trial design (2014) (7)
- Interventions to Influence Opioid Prescribing Practices for Chronic Noncancer Pain: A Systematic Review and Meta-Analysis. (2020) (7)
- Thrombophilia and cerebral vein thrombosis. (2008) (7)
- Perioperative Management for Congenital Factor XI Deficiency; A Systematic Review (2016) (7)
- Multicentre pharmacokinetic evaluation of rFVIII‐Fc (efmoroctocog alfa) in a real life and comparison with non‐extended half‐life FVIII concentrates (2020) (7)
- Overall prognosis of preschool autism spectrum disorder diagnoses. (2017) (7)
- Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age‐matched controls (2018) (6)
- First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System (2014) (6)
- Factor product utilization and health outcomes in patients with haemophilia A and B on extended half‐life concentrates: A Canadian observational study of real‐world outcomes (2021) (6)
- Point‐of‐care ultrasonography in haemophilia care: Training and competency for muscular haematomas (2018) (6)
- Clinical application of Web Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS‐Hemo): Patterns of blood sampling and patient characteristics among clinician users (2019) (6)
- Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study (2016) (6)
- Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study (2021) (6)
- Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH (2016) (6)
- The association between venous thromboembolism and physical inactivity in everyday life (2011) (6)
- Safety and efficacy of ximelagatran: meta-analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism. (2005) (6)
- Haemophilia in a real‐world setting: the value of clinical experience in data collection (2016) (6)
- Experimental evidences on the role of silica nanoparticles surface morphology on the loading, release and activity of three proteins (2019) (6)
- Systematic reviews of prognosis studies: a critical appraisal of five core clinical journals (2017) (5)
- Interpreting trial sequential analysis (2016) (5)
- Switching to Warfarin after 6-Month Completion of Anticoagulant Treatment for Cancer-Associated Thrombosis (2015) (5)
- Validating the "FACE" instrument using stakeholder perceptions of Feasibility, Acceptability, Cost and Equity in guideline implementation. (2020) (5)
- Venous Thromboembolism Recurrence after a First Episode of Provoked Venous Thrombosis Due to a Transient Risk Factor. A Systematic Review of the Literature (2008) (5)
- Plasma thrombin neutralization assay: pharmacokinetic applications. (1994) (5)
- Computer-Aided Systematic Review Screening Comes of Age (2017) (5)
- Context and Approach in Reporting Evaluations of Electronic Health Record–Based Implementation Projects (2020) (5)
- GRADE Guidance article 35: Update on rating imprecision for assessing contextualized certainty of evidence and making decisions. (2022) (5)
- Predicting Disease Recurrence in Patients with Previous Unprovoked Venous Thromboembolism: The DASH Prediction Score (2011) (5)
- Machine Learning Approaches to Retrieve High-Quality, Clinically Relevant Evidence From the Biomedical Literature: Systematic Review (2021) (5)
- The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A. (2018) (4)
- GRADE concept paper 2: Concepts for Judging Certainty on the Calibration of Prognostic Models in a Body of Validation Studies. (2021) (4)
- Impact of thrombophilia on arterial ischemic stroke or cerebral venous sinus thromboses in children: a systematic review & meta-analysis of observational studies (2010) (4)
- Residual vein thrombosis and D-dimer for optimizing duration of anticoagulation in idiopathic deep vein thrombosis. (2010) (4)
- Oral contraceptive use is a provoking factor for venous thromboembolism (2017) (4)
- Risk factors for bleeding in people living with hemophilia A and B treated with regular prophylaxis: A systematic review of the literature (2022) (4)
- Correction: A methodological survey of the analysis, reporting and interpretation of Absolute Risk ReductiOn in systematic revieWs (ARROW): a study protocol (2013) (4)
- Development and application of health outcome descriptors facilitated decision-making in the production of practice guidelines. (2021) (4)
- Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor (2015) (4)
- New methods facilitated the process of prioritizing questions and health outcomes in guideline development (2021) (4)
- How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines (2021) (4)
- Optimizing a literature surveillance strategy to retrieve sound overall prognosis and risk assessment model papers (2021) (3)
- Predictors of treatment adherence in patients with chronic disease using the Multidimensional Adherence Model: unique considerations for patients with haemophilia (2020) (3)
- Tools for Identifying Reliable Evidence and Implementing it in Everyday Clinical Care (2013) (3)
- Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products (2021) (3)
- The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B (2021) (3)
- Recombinant Factor VIIa Concentrate versus Plasma-derived Concentrates for the Treatment of Acute Bleeding Episodes in Persons with Haemophilia and Inhibitors (2011) (3)
- Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B. (2021) (3)
- Successful treatment of Dieulafoy's disease in a von Willebrand patient. (2002) (3)
- Non-Anticoagulant Actions of Glycosaminoglycans (1996) (3)
- A Deep Learning Approach to Refine the Identification of High-Quality Clinical Research Articles From the Biomedical Literature: Protocol for Algorithm Development and Validation (2021) (3)
- The D-dimer (DD) test to establish the duration of anticoagulation after a first unprovoked episod of venous thromboembolism (VTE); the prospective randomized “Prolong” Study on behalf of the Italian Federation of Anticoagulation Clinics (FCSA) (2005) (3)
- Knowledge translation strategies for sharing evidence-based health information with older adults and their caregivers: findings from a persona-scenario method (2021) (3)
- Comparisons of Factor Consumption for Routine Prophylaxis And Bleeding During Episodic Therapy With Recombinant Factor Viii Fc Fusion Protein and Conventional Recombinant Factor Viii. (2015) (3)
- Effect of dermatan sulphate on activated partial thromboplastin time determined with different reagents. (1997) (3)
- Good or best practice statements: proposal for the operationalisation and implementation of GRADE guidance (2022) (3)
- Choice of End-points in Assessing the Efficacy of Post-discharge Prophylaxis for Venous Thromboembolism (1998) (3)
- Deep Learning Method to Automatically Identify Reports of Scientifically Rigorous Clinical Research from the Biomedical Literature (2018) (3)
- Prophylaxis of venous thromboembolism in elderly patients with multimorbidity Maura MarcucciAlfonso IorioAlessandro NobiliMauro TettamantiLuca PasinaCodjo Djignefa Djade • Alessandra MarengoniFrancesco SalernoSalvatore CorraoPier Mannuccio Mannucci • REPOSI (REgistro POliterapie SocietaItaliana di M (2013) (3)
- Home therapy for inherited bleeding disorders in South Africa: Results of a modified Delphi consensus process. (2019) (2)
- Heart failure and chronic kidney disease in a registry of internal medicine wards (2014) (2)
- Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dyoxigenase-1 and Heme Oxygenase-1 (2020) (2)
- Serine base exchange enzyme in porcine lyophilised platelets: enzyme properties and modulation by AIF4-and different types of heparin (2004) (2)
- Protocol for a scoping review of outcomes in clinical studies of interventions for venous thromboembolism in adults (2020) (2)
- RANDOMISED, OPEN, PROSPECTIVE, MULTICENTER PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ACTIVATED RECOMBINANT FACTOR VIIA (NOVOSEVEN) IN ACUTE INTRACEREBRAL HAEMORRHAGE IN PATIENTS TREATED WITH ORAL ANTICOAGULANT OR ANTIPLATELET AGENTS (2007) (2)
- Ruling out DVT using the Wells rule and a D-dimer test (2014) (2)
- Are placebo‐controlled trials ethical in areas where current guidelines recommend therapy? No (2006) (2)
- Seizures, headache and thrombocytopenia: diagnosis and treatment do not always come in a standard sequence (2007) (2)
- Table of Contents (2011) (2)
- Which actionable statements qualify as good practice statements In Covid-19 guidelines? A systematic appraisal (2022) (2)
- Development and internal validation of a clinical prediction model for the diagnosis of immune thrombocytopenia (2022) (2)
- Can evidence harm? Certainly not hemophilia treatment and community (2006) (2)
- Haemophilia at various stages of life: design of new therapeutic strategies through an interactive course--the Kogeniale project. (2013) (2)
- Second International Stroke Summit (2006) (2)
- Individual participant datameta-analyses compared with meta-analyses based on aggregate data (Review) (2016) (2)
- A personalized limited sampling approach to better estimate terminal half‐life of FVIII concentrates (2022) (2)
- Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders (2021) (2)
- Observational Study of Real-World Factor Utilization and Health Outcomes in Patients with Hemophilia in Canada (2018) (2)
- Factor Consumption for Prophylaxis and Treatment of Bleeding: Recombinant Factor Ix Fc Fusion Protein Compared With Conventional Recombinant Factor Ix. (2015) (2)
- A comparison of methods for prediction of pharmacokinetics across factor concentrate switching in hemophilia patients. (2019) (2)
- Evaluation of the sexual health in people living with hemophilia (2021) (2)
- Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company (2020) (2)
- The current state of adverse event reporting in hemophilia (2017) (1)
- Clinical efficacy and safety of moroctocog alfa (2011) (1)
- The Effect of Platelet Transfusion on Death in the Intensive Care Unit (2016) (1)
- Sexual Health in Patients with Hemophilia; The Insights from the Patient Reported Outcomes, Burdens and Experiences (PROBE) Study (2017) (1)
- Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates (2014) (1)
- Reflections on the Canadian Bleeding Disorders Registry: Lessons Learned and Future Perspectives (2022) (1)
- User-centered development and testing of the online PROBE survey and the myPROBE app and integration with the Canadian bleeding disorder registry. (Preprint) (2021) (1)
- An evaluation of the COVID-19 recommendation map identified diverging clinical and public health guidance (2022) (1)
- Comparison of single subject and population‐based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A (2021) (1)
- Women and Money in Australia: Across the Generations (2016) (1)
- Exploring some intersections between pharmacokinetics, factor VIII measurement and human morphometrics – impact of recent advances in haemophilia study design on our understanding of optimal haemophilia treatment (2017) (1)
- Clinical audit of the use of fresh frozen plasma in Umbria: study design and results of the pilot phase. (2008) (1)
- Translating Clinical Questions by Physicians Into Searchable Queries: Analytical Survey Study (2020) (1)
- Analysis of Hemophilia a Outcomes and Treatment Patterns Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry (2020) (1)
- Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies. (2009) (1)
- Modeling The Impact of Potential Differences In Real-Wolrd Adherence With Extended-Half-Life Vs. Conventional Factor Viii And Ix on Bleeding. (2015) (1)
- von Willebrand Factor-binding aptamer rondoraptivon pegol as treatment for severe and non-severe hemophilia A. (2022) (1)
- Comparative Assessment of the Performance of Pharmacokinetic Tools for Prophylactic Dosing of Antihemophilic Factor Recombinant Plasma/Albumin-Free Method (rAHF-PFM) Concentrate in Patients with Hemophilia A (2017) (1)
- Perioperative Management of Von Willebrand Disease, a Systematic Review and Meta-Analysis (2016) (1)
- Indoleamine 2,3-Dioxygenase and Peripheral Tolerance to Exogenous Factor VIII: A Multi-Centre Pilot Study (2011) (1)
- Developing a Two-Sided Intervention To Facilitate Shared Decision Making In Haemophilia: Decision Boxes For Clinicians and Brief Patient Decision Aids For Patients (2013) (1)
- A decisional model to individualize warfarin recommendations: Expected impact on treatment and outcome rates in a real-world population with atrial fibrillation. (2016) (1)
- Methodological considerations for investigating oral anticoagulation persistence in atrial fibrillation (2020) (1)
- Risk difference estimation and reporting in systematic reviews. (2012) (1)
- Inhibitor development in previously treated Haemophilia A patients: a systematic review, (2013) (1)
- THU0561 Clinical practice guideline for diagnosis and management of catastrophic antiphospholipid syndrome (2017) (1)
- Iatrogenic causes of an ICH: OAT therapy (2008) (1)
- Extended reporting guidance for vaccine effectiveness studies for variants of concern for COVID-19 (2022) (1)
- Hemophilia Experiences, Results and Opportunities (HERO) Study: US Respondent Demographics and Impact of Diagnosis On Career and Lifestyle Decisions and Quality of Life (2012) (1)
- Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia (2021) (1)
- Rate of inhibitor development in previously-untreated hemophilia A patients treated with plasma derived or recombinant factor VIII concentrates. A systematic review of the literature and meta-analysis (2010) (1)
- Switching from standard to extended half‐life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics (2022) (1)
- Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients (2019) (1)
- Indirect Comparison Of The Efficacy Of Recombinant Factor Viii Fc Fusion Protein And Other Factor Viii Products For ProphylaxisModeling The Effect Of Compliance (2014) (1)
- Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time (2021) (1)
- Knowledge translation strategies for sharing evidence-based health information with older adults and their caregivers: Findings from a co-design study (2021) (1)
- Target plasma factor levels for personalized treatment in hämophilia: a Delphi consensus statement (2017) (1)
- Low-Molecular-Weight and Unfractionated Heparin for Prevention of Venous Thromboembolism in Neurosurgery (2016) (1)
- Determinants of inhibitor development in previously treated hemophilia A patients (2015) (1)
- Desmopressin acetate (DDAVP) for preventing and treating bleeding in people with mild or moderate haemophilia A (2015) (1)
- Indirect Comparison Of The Efficacy Of Recombinant Factor Ix Fc Fusion Protein And Other Factor Ix Products For Prophylaxis: Simulating The Effect Of Compliance On Real-World Effectiveness (2014) (1)
- Translating Clinical Questions by Physicians Into Searchable Queries: Analytical Survey Study (Preprint) (2019) (1)
- Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics Are Similar across Different FVIII Products in Patients with Severe Hemophilia A (2019) (1)
- Selecting references that match constructs: the difficult job of citing the parachute hyperbole (2008) (1)
- von Willebrand factor propeptide variants lead to impaired storage and ER retention in patient‐derived endothelial colony‐forming cells (2022) (1)
- NON-ANTICOAGULANT ACTIONS OF GLYCOSAMINOGLYCANS Protein Binding Studies (1996) (1)
- Clinical Study Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A : Results of a Cohort Study (2014) (1)
- Clinical and Biological Determinants of Bleeding Manifestation in Congenital Factor XI Deficiency; A Systematic Review (2016) (1)
- Hemophilia Impacts Quality of Life (QoL) in Adult PWH at an Early Age, with Pain a Contributing Factor: US Results From the Hemophilia Experiences, Results and Opportunities (HERO) Study (2012) (1)
- Applied pharmacoeconomics: considerations to drive the choice of a prophylactic antithrombotic regimen (2003) (1)
- A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients. (2020) (1)
- WEB BASED SUPPORT FOR HAEMOPHILIA MANAGEMENT: AN INTER-REGIONAL NETWORK IN MIDDLE ITALY. (2008) (0)
- PP93 HTA Role In CoreHEM, A Multi-Stakeholder Core Outcome Set Project (2018) (0)
- Clinical Efficacy and Safety Versus Biological Response of Desmopressin (DDAVP) In Inherited Von Willebrand Disease (VWD) Types 1 and 2: Initial Results From the International Study Group on DDAVP In VWD In a Cohort of 229 Patients (2010) (0)
- An evidence rating service provided valid correlates of the clinical importance of medical articles and journals. (2019) (0)
- Associations between negative impact on employment or relationships and haemophilia treatment centre (HTC) and health care practioner utilisation: Global results from the haemophilia experiences, results and opportunities (HERO) study (2013) (0)
- Test-Retest Reliability Analysis of the Patient Reported Outcomes Burdens and Experiences (PROBE) (2016) (0)
- More about optimal choices in cardioembolism prevention (2011) (0)
- Prevalence of potentially inappropriate medications in a cohort of hospitalized elderly: Results from the REPOSI study (2013) (0)
- First Steps in Choosing Appropriate Instruments/Measurements for a Core Outcome Set: An Example from Corehem (2018) (0)
- Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry (2021) (0)
- Real-World Outcomes of Emicizumab in Hemophilia A with or without FVIII Inhibitors from the Canadian Hemophilia Bleeding Disorder Registry (2022) (0)
- Burden of Comorbid Diseases in Patients with Hemophilia: The Cross-Sectional Analysis of the Patient Reported Outcomes, Burden and Experiences (PROBE) Study (2017) (0)
- Serine base-eschange enzyme in commercially available porcine lyophilized platelets: different effect of unfractionated and low molecular weight heparin (1999) (0)
- do bleed rates and haemophilia treatment centre/provider utilisation vary with physical activity risk in adults with haemophilia: An analysis from the Hero study : Po 127 (2013) (0)
- A Systematic Review of Definitions and Reporting of Bleeding Outcome Measures in Hemophilia (2014) (0)
- Meta-Analysis of Observational Studies Sinovenous Thrombosis in Neonates and Children. A Systematic Review and Impact of Thrombophilia on Risk of Arterial Ischemic Stroke or Cerebral (2011) (0)
- External qualification of the Web‐Accessible Population Pharmacokinetic Service–Hemophilia (WAPPS‐Hemo) models for octocog alfa using real patient data (2021) (0)
- 2 coagulation disorders factor VIII and IX deficiency: an index of different clinical severity of the Comparison of the rates of joint arthroplasty in patients with severe (2013) (0)
- Potency-Adjusted Analyses of a Head-to-Head Pharmacokinetic Study of Damoctocog Alfa Pegol (BAY 94-9027) and Efmoroctocog Alfa (rFVIIIFc) in Patients with Severe Hemophilia A (2020) (0)
- Driving ahead with one eye on the rear view mirror What ’ s the future of Physiotherapy in Haemophilia care ? (2018) (0)
- Driving ahead with one eye on the rear view mirror What ’ s the future of Physiotherapy in Haemophilia care ? (2018) (0)
- Venous thrombotic risk assessment among factor V Leiden carriers undergone a thrombophilic screening by different types of indications (2004) (0)
- Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database (2020) (0)
- Cost‐utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada (2022) (0)
- Associations between inhibitors, treatment regimen, and bleed frequency and health care practitioner utilisation in the haemophilia treatment centre (HTC): Global results from the haemophilia experiences, results and opportunities (HERO) study (2013) (0)
- Fresh Frozen Plasma Transfusion Practice: A Regional Benchmark Study. (2009) (0)
- Oral anticoagulant therapy with POC device and remote computer monitoring in the setting of the Italian National Health System (INHS) (2003) (0)
- Review: Perioperative LMW heparin does not reduce mortality after surgery more than unfractionated heparin in patients with cancer (2008) (0)
- The Wells rule and a primary care rule were useful for ruling out deep venous thrombosis in primary care (2011) (0)
- High Efficacy of Combination Therapy with Pegylated Interferon and Ribavirin in Hemophiliacs with Chronic Hepatitis C. (2005) (0)
- Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study (2022) (0)
- PROSPECTIVE ASSESSMENT OF CLINICAL ENDPOINTS OF VKA TREATMENT IN A PRIMARY CARE COMPUTER ASSISTED MANAGEMENT MODEL (2007) (0)
- Clinical validation of a new algorithm for computerized dosing of vitamin K antagonist therapy: a retrospective simulation study (2013) (0)
- Routine Double Filtration Plasmapheresis Affects Hemostatic Proteins and Prolongs Clotting Tests (2019) (0)
- Erratum to “Small intestinal bacterial overgrowth and warfarin dose requirement variability” [Thromb. Res. 126 (1) (2010) 12–17] (2013) (0)
- Theoretical Foundation for Research in Communication using Information and Communication Technology Devices in Healthcare: An Interdisciplinary Scoping Review (2013) (0)
- Prothrombotic risk factors in patients with ischaemic stroke or tia under age 50 (2000) (0)
- Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia (2022) (0)
- Low-molecular-weight-heparin treatment and cancer: pooled analysis of 908 patients treated for three months and review of the literature (2002) (0)
- A 9-factor score predicted 2-year risk for bleeding in outpatients with, or at high risk for, atherothrombosis (2010) (0)
- Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments (2020) (0)
- Response: Comparing joint arthroplasties in severe hemophilia A with severe hemophilia B (2009) (0)
- Ten-Year Canadian National Prospective Data On Utilization of Anti-Hemophilic Concentrates: Indications and Trends (2012) (0)
- Summarizing the theoretical foundation for hospital communication research: A scoping review of interdisciplinary literature. (2012) (0)
- Thrombosis in congenital a-, dys- and hypofibrinogenemia (2017) (0)
- Systematic Review of Randomized Controlled Trials of Prophylactic Clotting Factor Concentrate in Hemophilia. (2005) (0)
- Assessment of Recurrence Risk After Unprovoked Venous Thromboembolism (2011) (0)
- Low-molecular-weight heparin treatment and cancer: pooled analysis of 908 patients treated for three months (2002) (0)
- EffectivenessofComputerizedDecisionSupportSystems LinkedtoElectronicHealthRecords:ASystematicReview (2014) (0)
- Absence of Interaction Between Influenza Vaccination and Oral Anticoagulant Therapy: A Randomized Blinded Clinical Trial (2005) (0)
- Plasma homocysteine measurement: comparison of three different assay methods in plasma from vascular patients (1999) (0)
- Elderly patients treated with oral anticoagulant: a prospective cohort study (1999) (0)
- Derivation of a Pharmacokinetic Model to Include a Plasma-Derived, von Willebrand Factor-Containing Factor VIII (Koate®-DVI) Concentrate and its Low-Dose Use (2021) (0)
- Perioperative Outcomes Associated with Inhibitor Status in Patients with Hemophilia - a Retrospective Cohort Study (2021) (0)
- Prospective Study of the Immunological Mechanisms of Immune Tolerance Induction in Severe Haemophilia a Patients with Inhibitors: Preliminary Analysis of a Multi-Center Longitudinal Study (2018) (0)
- Warfarin Resumption after Intracranial Hemorrhage: A Systematic Review and Meta-Analysis (2016) (0)
- OAT with POC devices and remote computer monitoring in the setting of the Italian NHS: a controlled clinical trial (2004) (0)
- Haemophilia clinical care and research needs: Assessing priorities (2018) (0)
- Understanding intravenous iron ordering practices for inpatients and outpatients at a large academic institution (2016) (0)
- Bleeding in Patients Receiving Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis (2015) (0)
- Sexual issues in people with haemophilia: Awareness and strategies for overcoming communication barriers (2021) (0)
- Interim Canadian Data from a Prospective, Observational Study of Routine Clinical Use of a Von Willebrand Factor Concentrate (Wilate®) (2016) (0)
- Utilization of a surgical database to provide care and assess perioperative treatment and outcomes in patients with bleeding disorders (2021) (0)
- Post-discharge deep-vein thrombosis after orthopaedic surgery (1996) (0)
- Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature. (2009) (0)
- Pharmacokinetics of the reformulated B-domain deleted recombinant factor VIII concentrate using chromogenicand one-stage assays with pooled normal plasma and refacto laboratory standard (2007) (0)
- Corrigendum (1995) (0)
- Prothrombin 202120A mutation in Behcet’s disease (1999) (0)
- Venous thromboembolism prophylaxis in elderly patients admitted to Italian internal medicine wards (2013) (0)
- Validation and Updating of a Prognostic Survival Model The Vienna Prediction Model (2013) (0)
- A Predictive Model for the Development of High-Responding Inhibitor In Children with Severe and Moderate Hemophilia A- Results of a Multicenter Cohort Study (2010) (0)
- Safety and Effectiveness of Desmopressin for the Management of Delivery and Major Surgery in Patients with Mild-Moderate Von Willebrand Disease: Final Analysis of the Prodeswil Study (2015) (0)
- Creating a Population Model for PK-Tailored Dosing Using Real-World Data from the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) Platform (2018) (0)
- Clinical efficacy and safety of DDAVP with or without tranexamic acid in inherited VWD: final results of the prospective and international study on 229 patients (2013) (0)
- User-centered development and testing of the online PROBE survey and the myPROBE app, and integration with the Canadian bleeding disorder registry. (Preprint) (2021) (0)
- Inhibition of fluid phase and fibrin bound thrombin: effect of heparin, r-hirudin, PEG-rm-hirudin and a thrombin exosite inhibitor (2000) (0)
- [Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A]. (2019) (0)
- Low-molecular-weight heparin and cancer survival: pooled analysis of 1726 patients treated for three months (2004) (0)
- Prevalence and Determinants of Bleeding in Severe Von Willebrand Disease Type 3: Results of Retro/Prospective Studies in a Cohort of 105/52 Italian Patients. (2009) (0)
- Does higher risk activity change bleed frequency and haemophilia treatment center/provider utilisation in children with haemophilia: an analysis from the HERO study (2013) (0)
- Installing FVIII-Specific Tolerance in Hemophilia Via Engagement of the Aryl Hydrocarbon Receptor By Tryptophan Derivatives (2016) (0)
- Thrombotic risk and laboratory pattern 91 consecutive patients with lupus anticoagulant and/or anticardiolipin antibodies (2001) (0)
- Answering relevant research questions via careful observation of clinical practice: a fresh look at the old way forward (2014) (0)
- Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature (2022) (0)
- Thrombolytic and haemorrhagic effects of bolus doses of rt-PA and A hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935) (1992) (0)
- Machine Learning Approaches to Retrieve High-Quality, Clinically Relevant Evidence From the Biomedical Literature: Systematic Review (Preprint) (2021) (0)
- PROSPECTIVE STUDY OF THE IMMUNOLOGICAL MECHANISMS OF IMMUNE TOLERANCE INDUCTION IN HAEMOPHILIA A PATIENTS WITH INHIBITORS (2017) (0)
- Evaluation of Plasma-Derived FVII Efficacy for the Treatment of Bleeding in a Murine Model of Hemophilia a (2017) (0)
- Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization (2019) (0)
- VP57 Test-Retest Reliability Analysis Of The Patient Reported Outcomes Burdens And Experiences (PROBE) Study Questionnaire Test-Retest Reliability Analysis Of The PROBE Study Questionnaire (2017) (0)
- The effect of influenza vaccination in patients on long-term oral anticoagulant therapy (2006) (0)
- Efficacy of influenza vaccination in elderly persons on long-term oral anticoagulation therapy (2006) (0)
- The landscape of strongholds (2016) (0)
- Auto Machine Learning Approaches to Refine the Identification of High-Quality Clinical Research Articles from The Biomedical Literature: A Study Protocol (Preprint) (2021) (0)
- Recommendations and guidelines for creating scholarly biomedical journals: A scoping review (2023) (0)
- User-Centered Development and Testing of the Online Patient-Reported Outcomes, Burdens, and Experiences (PROBE) Survey and the myPROBE App and Integration With the Canadian Bleeding Disorder Registry: Mixed Methods Study (2022) (0)
- GRADE Guidance 36: Updates to GRADE's approach to addressing inconsistency. (2023) (0)
- Accuracy and Acceptability of Wrist-Wearable Activity Tracking Devices: A Systematic Review of the Literature. (Preprint) (2021) (0)
- Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients (2019) (0)
- Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes. (2023) (0)
- Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients (2019) (0)
- Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: A scoping review (2022) (0)
- Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Alfonso Iorio?
Alfonso Iorio is affiliated with the following schools: